Xhale, a Delaware corporation, was founded in late 2005 based on intellectual property and patents licensed from the University of Florida. The company began product development on its SMART^® medication adherence monitoring technology and on a propofol monitor in 2006.

In 2008, the company began development of a third product line, the HyGreen^® hand hygiene monitoring and recording system. By 2010, Xhale had successfully commercialized HyGreen^®, and the product was spun out as a stand-alone company with a separate management team.

During 2008 through 2011 Xhale was awarded two Phase II SBIR grants from the National Institutes of Health (NIH), totaling more than $4 million, to supplement the investment made by the company in its technologies.

In 2010, Xhale in-licensed patents underlying the Assurance™ technology and began development of the Assurance™ product line.

Xhale is now focused on its SMART^®, Assurance™ and propofol monitoring product lines, and is preparing for their commercial launches in 2013. The company is privately held and private-equity funded.